Reckitt Benckiser Group Plc said it will start a strategic review of its pharmaceutical unit, pointing to the possible sale of a business that analysts say could fetch at least 1.5 billion pounds ($2.4 billion).
Reckitt Benckiser Group Plc, the maker of Nurofen painkillers and Durex condoms, said it will start a strategic review of its pharmaceutical unit following calls from analysts for it to exit the business.
U.K. stocks gained for a ninth day as Reckitt Benckiser Group Plc and BHP Billiton Ltd. rallied after posting quarterly results, while a report showed that the U.S. economy created fewer jobs last month.
Unilever Chief Executive Officer Paul Polman will next week report one of the worst quarters of sales growth in his five-year tenure amid a slowdown in emerging markets. Making matters worse is that an expected recovery in the U.S., his single largest market, has failed to materialize.
Unilever, the world’s second-largest consumer-goods maker, said sales growth weakened in the third quarter amid a further slowdown in emerging markets, sending the shares down the most in almost two years.